Asclepii to Showcase FDA-Cleared Poseidon™ Nanosilver Hydrogel at Vizient Event

Asclepii, a Cleveland-based company specializing in modern wound care solutions, will showcase its FDA 510(k)-cleared Poseidon™ Nanosilver Hydrogel at Vizient’s Innovative Technology Exchange in Las Vegas on September 24. This event, which is part of Vizient’s Innovative Technology Program, provides a unique platform for healthcare providers to engage with innovative products and services that may shape the future of clinical care and business models.

The annual Innovative Technology Exchange offers selected suppliers the opportunity to demonstrate their products to supply chain and clinical leaders from Vizient’s hospital clients and subject matter experts. Asclepii’s participation marks a significant milestone in the company’s commercial expansion, as its Poseidon™ Nanosilver Hydrogel will be presented to health system leaders who are key decision-makers in modern wound care purchasing.

“Advanced medicine has increasingly focused on sophistication and accessibility,” stated Franco Kraiselburd, CEO and Co-Founder of Asclepii. “Vizient’s Innovative Technology Exchange is a forum where we can present our technology to those who are shaping the future of healthcare, ensuring that our products are not just innovative but also practical and cost-effective.”

According to Kelly Flaharty, associate vice president of contract operations at Vizient, the Innovative Technology Exchange serves as a distinctive platform for healthcare providers to engage with products that can enhance clinical care and business models. “We are pleased to invite Asclepii to participate in this year’s event,” said Flaharty.

Asclepii’s Poseidon™ Nanosilver Hydrogel is an FDA 510(k)-cleared medical device designed with an ultra-low 1 ppm nanosilver formulation and validated to ISO 10993 biocompatibility standards. The product is available in prescription and over-the-counter formats and is reimbursable under HCPCS code A6248 (PDAC-certified).

In addition to Poseidon™, Asclepii is also developing Artemis Wound Matrix, a regenerative collagen-based dressing currently in development for the management of more complex chronic wounds. The company’s work is grounded in research from Case Western Reserve University and supported by clinical partnerships with Cleveland Clinic and University Hospitals, ensuring that its products are not only scientifically advanced but also clinically validated.

“Poseidon™ Nanosilver Hydrogel represents a significant step forward in the accessibility of effective wound care solutions,” said Kraiselburd. “By presenting our technology at Vizient’s Innovative Technology Exchange, we are aligning ourselves with the leaders in healthcare who are committed to improving patient outcomes through innovative and practical solutions.”

Since 2003, Vizient has reviewed over 1,700 product submissions as part of its Innovative Technology Program, which includes the product review of supplier-submitted technologies by provider-led councils. The event offers an opportunity for suppliers like Asclepii to introduce their products to the right audience, potentially influencing future healthcare practices and product adoption.